Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: Correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation

Clinical Immunology

Volumn 92, Issue 1, 1999, Pages 103-110

  Di Marzio, Luisa ^a   Moretti, Sonia ^b   D'Alò, Simona ^a   Zazzeroni, Francesca ^a   Marcellini, Sonia ^b   Smacchia, Camillo ^c   Alesse, Edoardo ^a   Cifone, M Grazia ^a   De Simone, Claudio ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c San Patrignano Medical Center   (Italy)

Author keywords

Acetyl L carnitine; Apoptosis; Ceramide; HIV infection; IGG 1

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; LEVACECARNINE; SOMATOMEDIN C;

ADULT; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CLINICAL ARTICLE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TREATMENT OUTCOME;

EID: 0032976918     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4727     Document Type: Article

References (51)

1. De Grandis D., Santoro L., Di Benedetto P. l-acetylcarnitine in the treatment of patients with peripheral neuropathies: A short term, double-blind clinical study of 426 patients. Clin. Drug Invest. 10:1995;317-322.
2. Gougeon M. L., Montagnier L. Apoptosis in AIDS. Science. 260:1993;1269-1270.
3. Ameisen J. C., Estaquier J., Idziorek T., De Bels F. The relevance of apoptosis to AIDS pathogenesis. Trends Cell Biol. 5:1995;27-40.
4. Finkel T. H., Banda N. K. Indirect mechanisms of HIV pathogenesis: How does HIV kill T cells. Curr. Opin. Immunol. 6:1994;606-615.
5. Gougeon M. L. Does apoptosis contribute to T cell depletion in human immunodeficiency virus infection. Cell Death Diff. 2:1995;1-8.
6. Groux H., Torpier G., Monte D., Mouton Y., Capron A., Ameisen J. C. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J. Exp. Med. 175:1992;331-340.
7. Gougeon M. L., Lecoeur H., Dulioust A., Enouf M.-G., Crouvoisier M., Goujard C., Debord T., Montagnier L. Programmed cell death in peripheral lymphocytes from HIV-infected persons. J. Immunol. 156:1996;3509-3520.
8. Famularo G., De Simone C., Tzantzoglou S., Trinchieri V. Apoptosis, anti-apoptotic compounds and TNF-α release. Immunol. Today. 15:1994;495-496.
9. Famularo G., Moretti S., Marcellini S., Trinchieri V., Tzantzoglou S., Santini G., Longo A., De Simone C. Acetyl-l-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS. 11:1997;185-190.
10. Di Marzio L., Alesse E., Roncaioli P., Muzi P., Moretti S., Marcellini S., Amicosante G., De Simone C., Cifone M. G. Influence of l-carnitine on Fas crosslinking-induced apoptosis and ceramide generation in T cell lines: Correlation with its effects on purified acidic and neutral sphingomyelinases in vitro. Proc. Assoc. Am. Phys. 109:1997;154-163.
11. Cifone M. G., Alesse E., Di Marzio L., Ruggeri B., Zazzeroni F., Moretti S., Famularo G., Steinberg S. M., Vullo E., De Simone C. Effect of l-carnitine treatment in vivo on apoptosis and ceramide generation in peripheral blood lymphocytes from AIDS patients. Proc. Assoc. Am. Phys. 109:1997;146-153.
12. Moretti S., Alesse E., Di Marzio L., Zazzeroni F., Ruggeri B., Marcellini S., Famularo G., Steinbergh S. M., Boschini A., Cifone M. G., De Simone C. Effect of l-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: A pilot study. Blood. 91:1998;3817-3824.
13. Cossarizza A., Mussini C., Mongiardo N., Borghi V., Sabbatini A., De Rienzo B., Franceschi C. Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome. AIDS. 11:1997;19-26.
14. Lowe W. L. Jr. Insulin-like growth factors. Sci. Am. Sci. Med. 1996;62-71.
15. Le Roith D. Insulin-like growth factors. Semin. Med. Beth Israel Deaconess Med. Center. 336:1997;633-640.
16. D'Mello S. R., Galli C., Ciotti T., Calissano P. Induction of apoptosis in cerebellar granule neurons by low potassium: Inhibition of death by insulin-like growth factor I and cAMP. Proc. Natl. Acad. Sci. USA. 90:1993;10989-10993.
17. Froesch E. R., Schmid C., Schwander J., Zapf J. Actions of insulin-like growth factors. Annu. Rev. Physiol. 47:1985;443-467.
18. Buerke M., Murohara T., Skurk C., Nuss C., Tomaselli K., Lefer A. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc. Natl. Acad. Sci. USA. 92:1995;8031-8035.
19. Gluckman P., Klempt N., Guan J., Mallard C., Sirimanne R., Dragunow M., Klempt M., Singh K., Williams C., Nikolics K. A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury. Biochim. Biophys. Res. Commun. 182:1992;593-599.
20. Le Roith D., Clemmons D. R., Nessley P., Rechler M. M. Insulin-like growth factors in health and disease. Ann. Intern. Med. 116:1992;854-862.
21. Le Roith D., Adamo M., Werner H., Roberts C. T. Jr. Insulin-like growth factors, and their receptors as growth regulators in normal physiology and pathological states. Trends Endocrinol. Metab. 2:1991;134-139.
22. Le Roith D., Werner H., Beitner-Johnson D., Roberts C. T. Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 16:1995;143-163.
23. McCubrey J. A., Stillman L. S., Mayhew M. W., Algate P. A., Dellow R. A., Kaleko M. Growth promoting effects of insulin-like growth factor 1 (IGF-1) on hematopoietic cells: Overexpression of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor dependent cells by ligand dependent mechanism. Blood. 78:1991;921-929.
24. Rodriguez-Tarduchy G., Collins M. K. L., Garcia I., Lopez-Rivas A. Insulin-like growth factor I inhibits apoptosis in IL-3-dependent hematopoietic cells. J. Immunol. 149:1992;535-599.
25. Harrington E. A., Bennett M. R., Fanidi A., Evan G. I. c-myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 14:1994;3286-3295.
26. Jung Y.-K., Miura M., Yuan J. Suppression of interleukin-1β-converting enzyme-mediated cell death by insulin-like growth factor. J. Biol. Chem. 271:1996;5112-5117.
27. Sell C., Baserga R., Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res. 55:1995;249-252.
28. Kulik G., Klippel A., Weber M. J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 17:1997;1595-1606.
29. Jones J. I., Clemmons D. R. Insuline-like growth factors and their binding proteins: Biological actions. Endocr. Rev. 16:1995;3-34.
30. Le Roith D., Yanowski J., Kaldjian E. P., Jaffe E. S., Le Roith T., Purdue K., Cooper B. D., Pyle R., Adler W. The effects of growth hormone and insulin-like growth factor 1 on the immune systems of aged female monkeys. Endocrinology. 137:1996;1071-1079.
31. Auernhammer C. J., Strasburger C. J. Effects of growth hormone and insulin-like growth factor 1 on the immune system. Eur. J. Endocrinol. 133:1993;633-643.
32. Kelley K. W. The role of growth hormone in modulation of the immune response. Ann. N.Y. Acad. Sci. 594:1990;95-103.
33. Kiess W., Malozowski S., Gelato M., Butenand O., Doerr H., Crisp B., Eisl E., Maluish A., Belohradsky B. H. Lymphocyte subset distribution and natural killer activity in growth hormone deficiency before and during short-term treatment with growth hormone releasing hormone. Clin. Immunol. Immunopathol. 48:1988;85-94.
34. Lave L., Pizzo P. A., Butler K., Cutler G. B. Growth and neuroendocrine dysfunction in children with acquired immunodeficiency. J. Pediatr. 117:1990;541-545.
35. Lieberman S. A., Butterfield G. F., Harison D., Hoffman A. R. Anabolic effects of recombinant insulin-like growth factor-1 in cachectic patients with the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 78:1994;404-410.
36. Frost R. A., Fuhrer J., Steigbigel R., Mariuz P., Lang C. H., Gelato M. C. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin. Endocrinol. 44:1996;501-514.
37. Mulligan K., Grunfeld C., Hollerstein M. K., Neese R. A., Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 77:1993;956-962.
38. Waters D., Danska J., Hardy K., Koster F., Qualls C., Nickell D., Nightingale S., Gesundheit N., Watson D., Schade D. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 125:1996;865-872.
39. Schambelan M., Mulligan K., Grunfeld C., Daar E. S., LaMarca A., Kotler D. P., Wang J., Bozzette S. A., Breitmeyer J. B. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Ann. Intern. Med. 125:1996;873-882.
40. Ellis K. J., Lee P. D., Pivarnik J. M., Bukar J. G., Gesundheit N. Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor 1 and growth hormone. J. Clin. Endocrinol. Metab. 81:1996;3033-3038.
41. Lee P. D. K., Pivarnick M., Bukar J. G., Muurahainen N., Berry P. S., Skolnik P. R., Nerad J. L., Kusdy K. A., Jackson L., Kenneth J. E., Gesundheit N. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J. Clin. Endocrin. Metab. 81:1996;2968-2975.
42. Schmid L., Uttenbogaart C. H., Keld B., Giorgi J. V. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J. Immunol. Methods. 170:1994;145-157.
43. De Simone C., Cifone M. G., Alesse E., Steinberg S. M., Di Marzio L., Moretti S., Famularo G., Boschini A., Testi R. Cell-associated ceramide in HIV-1-infected subjects. AIDS. 10:1996;675-676.
44. De Simone C., Cifone M. G., Roncaioli P., Moretti S., Famularo G., Alesse E., Boschini A., Testi R. Ceramide, AIDS, and long-term survivors. Immunol. Today. 17:1996;48.
45. De Simone C., Famularo G., Cifone M. G., Mitsuya H. HIV-1 infection and cellular metabolism. Immunol. Today. 17:1996;256-258.
46. Clark R., Strasser J., McCabe S., Robbins K., Jardieu P. Insulin-like growth factor-I stimulation of lymphopoiesis. J. Clin. Invest. 92:1993;540-548.
47. Cifone M. G., De Maria R., Roncaioli P., Rippo M. R., Azuma M., Lanier L. L., Santoni A., Testi R. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J. Exp. Med. 177:1994;1547-1552.
48. Cifone M. G., Roncaioli P., De Maria R., Camarda G., Santoni A., Ruberti G., Testi R. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: Sequential involvement of phosphatidylcholine-specific phospholipase and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J. 14:1995;5859-5868.
49. Obeid L. M., Linardic C. M., Karolak L. A., Hannun Y. A. Programmed cell death induced by ceramide. Science. 259:1993;1769-1771.
50. Jarvis W., Kolesnick R. N., Fornari F. A., Traylor R. S., Gerwitz D. A., Grant S. Induction of apoptotic damage and cell death by activation of the sphingomyelin pathway. Proc. Natl. Acad. Sci. USA. 91:1994;73-77.
51. Gulbins E., Bissonnette R., Mahboubi A., Martin S., Nishioka W., Brunner T., Baier G., Baier-Bitterlich G., Byrd C., Lang F., Kolesnik R., Altman A., Green D. Fas-induced apoptosis is mediated via a ceramide-initiated RAS signalling pathway. Immunity. 2:1995;341-351.